{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:56:33Z","timestamp":1793094993601,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lipoprotein(a) [Lp(a)] is a causal and independent cardiovascular risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis, with elevated levels observed in approximately 20% of the general population. Plasma Lp(a) concentrations are predominantly determined by genetic factors, particularly polymorphisms of the LPA gene, which modulate apolipoprotein(a) [apo(a)] size and influence its hepatic synthesis. Structurally, Lp(a) consists of an LDL-like particle containing apolipoprotein B100, covalently bound to apo(a), conferring markedly enhanced atherogenic, pro-inflammatory, and prothrombotic properties compared with an LDL particle. In the absence of therapies specifically approved for Lp(a) reduction, current clinical management relies on an intensive approach to global cardiovascular risk reduction. ESC\/EAS guidelines recommend aggressive lowering of LDL cholesterol, particularly through high-intensity statin therapy and, in patients at high or very high risk, the addition of ezetimibe and PCSK9 inhibitors, in order to mitigate the residual risk associated with elevated Lp(a) levels. Lipoprotein apheresis represents the only intervention capable of producing a substantial and immediate reduction in Lp(a); however, its use is limited to selected patients due to its invasive nature and limited availability. In parallel, innovative therapies targeting LPA gene silencing\u2014such as antisense oligonucleotides and small interfering RNA\u2014as well as oral agents inhibiting Lp(a) assembly, are in advanced stages of development. These approaches have demonstrated Lp(a) reductions of up to 80\u201390%, offering concrete prospects for a causal therapeutic strategy, pending the results of cardiovascular outcome trials.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suag048","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:46:42Z","timestamp":1772023602000},"page":"v181-v186","source":"Crossref","is-referenced-by-count":4,"title":["Focus on lipoprotein(a)"],"prefix":"10.1093","volume":"28","author":[{"given":"Marta","family":"Biolo","sequence":"first","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University Hospital\u2014Padua , Via Giustiniani 2, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Portinari","sequence":"additional","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University Hospital\u2014Padua , Via Giustiniani 2, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Goffi","sequence":"additional","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University Hospital\u2014Padua , Via Giustiniani 2, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Berti","sequence":"additional","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University Hospital\u2014Padua , Via Giustiniani 2, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Bertocco","sequence":"additional","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University Hospital\u2014Padua , Via Giustiniani 2, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Previato","sequence":"additional","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University Hospital\u2014Padua , Via Giustiniani 2, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Zambon","sequence":"additional","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University Hospital\u2014Padua , Via Giustiniani 2, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University Hospital\u2014Padua , Via Giustiniani 2, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7096-5201","authenticated-orcid":false,"given":"Alberto","family":"Zambon","sequence":"additional","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University Hospital\u2014Padua , Via Giustiniani 2, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026050607121491500_suag048-B1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjcard.2025.02.034","article-title":"Lipoprotein(a)\u2014from biomarker to therapy: a review for the clinician","volume":"245","author":"Jha","year":"2025","journal-title":"Am J Cardiol"},{"key":"2026050607121491500_suag048-B2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026050607121491500_suag048-B3","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026050607121491500_suag048-B4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026050607121491500_suag048-B5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"2026050607121491500_suag048-B6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026050607121491500_suag048-B7","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"2026050607121491500_suag048-B8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis","volume":"349","author":"Boffa","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026050607121491500_suag048-B9","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1161\/CIRCULATIONAHA.125.073855","article-title":"Oxidized phospholipids, lipoprotein(a), and cardiovascular outcomes after acute coronary syndrome","volume":"152","author":"Tsimikas","year":"2025","journal-title":"Circulation"},{"key":"2026050607121491500_suag048-B10","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050607121491500_suag048-B11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026050607121491500_suag048-B12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"2026050607121491500_suag048-B13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","article-title":"Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation","volume":"9","author":"Nurmohamed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026050607121491500_suag048-B14","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.jacc.2025.02.024","article-title":"Lipoprotein(a) cardiovascular risk explained by LDL cholesterol, non-HDL cholesterol, ApoB, or hsCRP is minimal","volume":"85","author":"Thomas","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026050607121491500_suag048-B15","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050607121491500_suag048-B16","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US family heart database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050607121491500_suag048-B17","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.numecd.2023.07.019","article-title":"Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA)","volume":"33","author":"Chiesa","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026050607121491500_suag048-B18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026050607121491500_suag048-B19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00392-025-02833-y","article-title":"A practical guide to the management of dyslipidaemia","volume":"115","author":"Siegel","year":"2026","journal-title":"Clin Res Cardiol"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/advance-article-pdf\/doi\/10.1093\/eurheartjsupp\/suag048\/67302887\/suag048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/28\/Supplement_5\/v181\/67302887\/suag048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/28\/Supplement_5\/v181\/67302887\/suag048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:12:20Z","timestamp":1778065940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/28\/Supplement_5\/v181\/8514536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":19,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suag048","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,11]]}}}